Introduction
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, adult onset neurodegenerative disorder characterized by degeneration and loss of motoneurons in the cerebral cortex, brain stem and spinal cord, leading to muscle wasting and weakness, and eventually to death within 5 years after the onset of its clinical symptoms. 1, 2 The proposed pathogenetic mechanisms of ALS, albeit not fully elucidated, include oxidative stress, protein aggregation, mitochondrial dysfunction, impaired axonal transport, glutamate-mediated excitotoxicity and insufficient production of neurotrophic factors. 3, 4 There is no effective treatment for patients suffering from ALS.
Stem cell-based therapy has recently aroused a great deal of interest because of its therapeutic potential for neurological diseases, such as stroke, spinal cord injury, Parkinson's disease, Huntington disease and ALS. [5] [6] [7] Recent studies have indicated that it is possible to generate motoneurons in culture from stem cells that include embryonic stem cells and neural stem cells (NSCs). [8] [9] [10] [11] Mouse ES cell-derived motoneurons transplanted into motor neuron-injured rat spinal cord survived and extended axons into the ventral root, 9 and human embryonic germ cells transplanted into cerebrospinal fluid of rats with motoneuron injury migrated into the spinal cord and led to improved motor function. 12 Transplantation of NSCs isolated from the adult mouse brain in ALS mouse spinal cord was also effective in delaying disease progression. 13 These cell transplantation studies have shown functional improvement in animal models of ALS; however, it is unlikely that the observed effects are results of replacement of lost neurons and establishment of neural circuitry by the grafted cells. Although it is unrealistic to expect the transplantation of stem cells or stem cellderived motoneurons in ALS patients to replace lost neurons, to integrate into existing neural circuitry and restore motor function, provision of neurotrophic factors by transplanted stem cells to prevent cell death in host motoneurons is a realistic and achievable approach. 7 Recent studies have shown that the administration of vascular endothelial growth factor (VEGF) protected motoneurons against excitotoxin-mediated cell death in organotypic cultures and AMPA-infused rats, 14, 15 and significantly delayed disease onset and prolonged the survival of ALS animal models. [16] [17] [18] [19] VEGF is one of such growth factors that can be used in combination with transplanted stem cells to improve therapeutic efficiency of cellular transplantation. VEGF is an angiogenetic growth factor acting as a potent mitogen and survival factor for endothelial cells, 20, 21 smooth muscle cells, 22, 23 hepatocytes 24 and cardiomyocytes, 25, 26 and also known for neuroprotective effect against brain injury. 27, 28 Several recent studies have also shown that VEGF promoted cell survival pathways and blocked cell death in the ALS animal model. [16] [17] [18] [19] 29, 30 VEGF is the neurotrophic growth factor that can be used in combination with transplanted stem cells to improve therapeutic efficiency of cellular transplantation. The regulation of VEGF expression is complex and occurs at multiple levels, extending from transcription to translation. The expression of mutant SOD1 protein in ALS animals destabilizes VEGF mRNA and markedly downregulates protein production, and this dysregulation of VEGF posttranscriptional processing critically reduces the level of neuroprotective VEGF and accelerates the neurodegenerative process in ALS. 31 In fact, the VEGF levels in cerebrospinal fluid tended to be lower in ALS patients than in the normal population. [32] [33] [34] Considering the evidence of clinical improvement in ALS animal models after transplantation of stem cells [10] [11] [12] [13] and VEGF treatment, [16] [17] [18] [19] 29, 30 we wished to investigate whether the human NSCs overexpressing VEGF, by pairing clonal human NSCs with VEGF gene, can lead to the clinical improvement in SOD1G93A mouse model of ALS.
Results
Immunofluorescence microscopy indicated that all F3.VEGF cells express VEGF immunoreactivity, while only a small number of parental F3 cells express it ( Figure 1 ). The amount of VEGF165 released by F3 or F3.VEGF human NSCs into the culture medium was determined by a specific ELISA kit, and F3.VEGF cells released 1832.9 ± 14.8 pg ml À1 of VEGF165, which was approximately 4 times of VEGF165 release in the parental F3 cell culture (490.8 ± 10.6 pg ml À1 ) ( Figure 1 ). These results indicate that F3.VEGF cells were successfully transfected with a retroviral vector encoding human VEGF165 gene.
The SOD1G93A mutant mice were intrathecally injected with F3 or F3.VEGF cells before the appearance of clinical symptoms. A significant delay in disease onset was observed in F3.VEGF-treated mice as compared with F3-or phosphate-buffered saline (PBS)-treated mice, as assessed by rotatod test (122, 115 and 115 days, respectively, Po0.01), paw grip endurance test (121, 107 and 101 days, respectively, Po0.05) and extension reflex (101.5, 95 and 95 days, respectively, Po0.01) (Figures 2a-c) . Intrathecal transplantation of F3.VEGF also significantly prolonged the survival of SOD1 transgenic mice as compared with F3-or PBS-treatment (145, 141 and 133 days, respectively, Po0.01) (Figure 2d ). Although statistical significance was not reached in F3-treated group, mice that were injected with F3 cells showed a delayed decline in paw grip endurance test and longer survival as compared with the controls.
To determine whether VEGF released by grafted F3.VEGF cells induces their own proliferation, expression of cell proliferation marker Ki-67 was examined in spinal cord sections (Supplementary Figure 1) Figure 3 ), while 12.3% of F3.VEGF cells were confirmed to migrate into the spinal cord parenchyma (Figure 4) .
The survival and integration of transplanted human NSCs at 2 and 4 weeks after transplantation was determined ( Figure 3 ). F3.VEGF cells located along the meninges were immunoreactionpositive for VEGF as expected from their overexpression of VEGF gene, but most of the cells were negative for glial fibrillary acidic protein reaction (Figure 3 ).
While at 2 weeks post-transplantation 1.6% of transplanted F3.VEGF cells was found inside of the spinal cord, at 4 weeks post-transplantation, 12.3% transplanted cells were found within the gray matter of the spinal cord (Table 1, Figure 4 ). Furthermore, transplanted cells (HuMit+) that express neuronal phenotype (MAP2+)
Human neural stem cells in mouse ALS model DH Hwang et al were found in the anterior horn of the spinal cord gray matter, indicating that the transplanted human NSCs expressing VEGF migrated into the gray matter, took the correct structural position in anterior horn and differentiate into MAP2+ neurons suggestive of differentiation into motoneurons ( Figure 4) .
To understand the mechanisms of neuroprotection provided by the transplanted F3.VEGF NSCs, we examined the expressions of several apoptosis-related proteins, including proapoptotic proteins (caspase 3 and Bax) and antiapoptotic cell survival proteins (Bcl-2 and Bcl-XL) in spinal cord tissues by western blot analysis ( Figure 5 ). Examined samples included the lumbar spinal cords containing transplanted F3.VEGF cells. The results show a considerable increase in the expression of caspase 3 and Bax in the control PBS-injected group, while in F3.VEGF group the expression of these proapoptotic proteins is significantly reduced ( Figure 5 ). In contrast, the levels of antiapoptotic proteins, Bcl-2 and Bcl-XL, were gradually reduced in PBS group, while in F3.VEGF group expression levels considerably increased ( Figure 5 ). These results suggest that the transplantation of 
Discussion
In this study, intrathecal transplantation of immortalized human NSCs overexpressing VEGF (HB1. F3.VEGF)
Significantly delayed disease onset and prolonged the survival of SOD1G93A mouse model of ALS. Our results suggest that this treatment modality might be of value in the treatment of ALS patients without significant adverse effects. Previous studies have shown that it is possible to generate motoneurons from stem cells that include embryonic stem cells and NSCs [8] [9] [10] [11] and delaying disease progression in ALS animal models. 5, 6, [10] [11] [12] A recent study has reported that the transplantation of mouse NSCs The survival and integration of transplanted human neural stem cells at 2 and 4 weeks post-transplantation was examined (total of 1 Â Human neural stem cells in mouse ALS model DH Hwang et al isolated from adult brain into the spinal cord of SOD mutant mice resulted in delayed disease onset and extended survival of animals, and that both VEGF and IGF growth factors released by the grafted cells are responsible for the neuroprotection. 13 The results of our study are in good agreement with the former study but there are several significant differences between the two studies. In our study (i) we have used human NSCs instead of mouse NSCs in the mouse model of ALS to advance the idea of using human NSCs in clinical trials in ALS patients in the future, (ii) the human NSCs used in our study, HB1.F3.VEGF, are homogenous, as they were clonally generated from a single human cell as compared with mouse primary neurosphere-derived Human neural stem cells in mouse ALS model DH Hwang et al stem cells that may contain non-stem cells including neuroglia, (iii) human NSCs were genetically modified to overexpress VEGF, so that VEGF, which is known to stimulate neuroprotection, angiogenesis and neurogenesis in vivo, could be steadily released in the grafted brain sties, and (iv) this human NSC line can be expanded to large number in culture in short time.
Several neurotrophic factors, such as brain-derived neurotrophic factor, ciliary neurotrophic factor and insulin-like growth factor, have been used for the treatment of ALS patients, but these clinical trials have all failed. 35 One of main reasons for the failure was inappropriate delivery of neurotrophic factors. These neurotrophic factors fail to cross the blood-brain barrier Human neural stem cells in mouse ALS model DH Hwang et al when delivered systemically, and are rapidly cleared from the circulation, preventing the administered neurotrophic factors from reaching the degenerating motoneurons. 36 In contrast to the systemic delivery of neurotrophic factors, our approach of transplanting human NSCs overexpressing VEGF in spinal cord intrathecally can assure delivery of VEGF for a long time steadily over a large area as the cells migrate and are integrated to the host tissue.
Recent studies have reported that the VEGF signaling pathway has an important role in spinal cord by promoting neuronal survival, and dysregulation of this pathway results in neuronal degeneration of motoneurons. In mice lacking the hypoxia-response element in the VEGF promoter, lower VEGF levels in spinal cord and progressive motor neuron degeneration resembling human ALS were demonstrated. 37 In SOD mutant mice, a significant downregulation of VEGF mRNA expression in spinal cord was found early in the course of the disease indicating that dysregulation of VEGF posttranscriptional processing reduces VEGF levels. 31 Subsequent follow-up human genetic studies have shown that 'low-VEGF' haplotypes in the VEGF promoter had an increased risk of ALS in the European population. 38 Several reports have also reported low VEGF levels in the colony-stimulating factor of ALS patients, [32] [33] [34] and the expression of both VEGF and VEGFR2 was downregulated on the anterior horn motoneurons as compared with the normal controls. 39 These studies have prompted us to use VEGF as a candidate trophic factor for treatment of the transgenic mouse model of ALS in this study.
Gene therapy is considered as one of the most promising approaches for treatment for inherited or acquired neurological disorders such as ALS that currently lack an effective treatment. Gene transfer to motoneurons can be achieved by direct injection of a viral vector encoding neurotrophic factor gene into the brain or spinal cord, or by ex vivo gene transfer using appropriate cell-type encoding neurotophic factor gene. 40 A single injection of a VEGF-expressing lentiviral vector into hindlimb muscle delayed disease onset and slowed disease progression in a transgenic G93ASOD1 ALS mouse model. 16 The treatment was effective even when the injection was administered at the onset of paralysis. Another study has reported that transplantation of human cortical progenitor cells expressing GDNF as modified by lentivirus vector into the lumbar spinal cord of rats with G93ASOD1 mutation improved survival of animals. 41 However, the direct injection of the genetically modified cells into the brain, spinal cord parenchyma or the ventricle is not easily accessible in clinical practice, if repetitive injections are necessary to achieve a desirable therapeutic effect. In this regard, intrathecal injection is an easy and safe method to introduce genetically modified cells into the lesion site to replenish lost neurons and provide supply of neurotrophic factors at the lesion sites.
Numerous neurotrophic factors such as brain-derived neurotrophic factor, GDNF, insulin-like growth factor-1 and VEGF have been demonstrated to prevent cell death of motoneurons in vitro and in vivo. 38, [41] [42] [43] Of these neurotrophic factors, VEGF is well known to have an important function in the pathogenesis of ALS. [31] [32] [33] [34] 37, 38 The genetically modified human NSCs we established, F3.VEGF cells, were confirmed to release four times of VEGF165, the most abundant and biologically active isoform in vivo, compared with the parental F3 cells as we have reported previously in animal models of stroke. 28 Ex vivo gene therapy by genetically modified cells to carry growth factor gene has no risk related with virus injection during the in vivo gene therapy, and the transplanted cells can deliver growth factor over a large area as the cells migrate and are integrated to the host brain tissue. Moreover, transplantation of NSCs may afford healthy glial cells that are derived from the NSCs to a diseased environment. This is crucial in modifying the progression of ALS because loss of glial cells is known to have an important function in the induction of motor neuron pathology. 44 Human stem cells are considered to be an ideal source for ex vivo gene therapy. 45 F3.VEGF cells were derived from F3 human NSC line and known to give rise to both neurons and glial cells. 28, 46 F3 human NSC line has been shown to improve clinical outcome following brain transplantation in animal models of stroke, 45, 46 spinal cord injury, 47 Parkinson disease, 48 Huntington disease 49 and lysosomal storage disease. 50 We identified that 12% of intrathecally introduced F3.VEGF cells migrated into the spinal cord and 52% cells were found along the meninges of the lumbar spinal cord 4 weeks after the injection. 
Human neural stem cells in mouse ALS model DH Hwang et al
The survival of transplanted human NSCs in this study was not significantly improved by immunosuppression with cyclosporine (data not shown) and similar observations were reported previously with human neural progenitor cells. 11 These authors grafted immortalized human neuronal progenitor cells into the rat spinal cord, and found only a small number of cells remained after 4 weeks despite of cyclosporine immunosuppresion. They concluded that the T-cell-mediated immunological attack was not involved in the cell death of transplanted cells because of the scarcity of CD5-labeled cells in the vicinity of the transplanted cells. It is likely that upregulation of proapoptotic signals such as caspase-3 and Bax in the grafted human NSCs is the main cause for the reduced survival of transplanted human NSCs as we have reported earlier in the mouse intracerebral hemorrhage stroke models. 28, 46 For the long-term survival of transplanted NSCs in vivo, introduction of proapoptotic gene in the NSCs in addition to the VEGF or other trophic factor gene might solve the problem.
Although the precise mechanism remains unclear, there are several possible explanations for the positive effects of intrathecal transplantation of F3.VEGF cell on behavioral improvement and prolonged survival in ALS mouse models. First, transplanted F3.VEGF cells migrated into the gray matter, integrated into the spinal cord anterior horn and differentiated into the neurons. Although the number of differentiated NSCs into the motoneurons was small, these findings indicate that transplanted F3.VEGF cells having a potential to differentiate into motoneurons and replace the lost motoneurons.
Second, the transplanted cells produced and released other growth factors in addition to VEGF. There was twofold increase in cell survival of transplanted F3.VEGF cells as compared with parental F3 cells at 4-week posttransplantation, and 90% of grafted F3.VEGF cells expressed VEGF marker at the time. Our previous study in the stroke animal models has shown that VEGF levels in F3.VEGF cell-grafted brain sites were 3 times those of F3-treated sites of mouse brain. 28 These results indicate that F3.VEGF cells in the spinal cord of ALS mice are capable of producing higher amount of VEGF than the parental F3 cells and thus provide neuroprotection against motoneuron degeneration and leading to improved behavioral outcome and extended survival time.
Third, the neuroprotective effect of VEGF in ALS mice is mediated by VEGF's ability to promote neuronal survival by active inhibition of apoptosis, which is accomplished by inhibiting the expression of proapoptotic factors as well as promoting the expression of antiapoptotic factors. Phosphatidylinositol 3-kinase (PI3-K) pathway, activated by VEGF, leads to the activation of Akt, an important player in survival signaling pathways. 29, 30 Activated Akt inhibits the proapoptotic factors Bad, caspase-9, GSK-3 and FKHR by phosphorylation. 29 VEGF also prevented the downregulation of Bcl-2 and survivin that implicated in antiapoptotic and/or antiexcitotoxic effects. 30 These results show a considerable increase in the expression of caspase 3 and Bax, both proapoptotic proteins, in the control PBS-injected group, whereas in F3.VEGF group the expression of these proapoptotic proteins is significantly reduced ( Figure 5 ). In contrast, the levels of antiapoptotic proteins Bcl-2 and Bcl-XL were reduced in the control PBS group, whereas in the F3.VEGF group, expression levels considerably increased ( Figure 5 ). These results suggest that the transplantation of F3.VEGFF cells provides neuroprotective effect in the diseased spinal cord by concomitant downregulation of proapoptotic proteins and upregulation of antiapoptotic proteins. Similarly, our previous study using the same F3.VEGF human NSCs in stroke animal model has shown that the VEGF treatment in vivo by human NSCs could reduce the expression of proapoptotic proteins caspase-3 and Bax, and the levels of antiapoptotic proteins (Bcl-2 and Bcl-xL) and survival signal molecules (p85, p110 and Akt1) were significantly higher as compared with the control group. 28 It is known that VEGF activates PI3-K/Akt pathway by VEGF receptors, and Akt, a serine-threonine protein kinase, exerts antiapoptotic effects by preventing the release of cytochrome c from mitochondria, by inactivating fork-head transcription factors by which transcription of proapoptotic genes is inhibited. 51, 52 These studies suggest that VEGF provide neuroprotective effect in diseases and injury in the central nervous system including ALS transgenic mice. [27] [28] [29] [30] 51, 52 In conclusion, F3.VEGF human NSCs intrathecally transplanted into spinal cord of ALS model mice were capable of replacing lost motoneurons and releasing VEGF, which provides neuroprotective effect by the production of antiapoptotic proteins and cell survivalpromoting molecules and downregulation of proapoptotic proteins. These features of F3.VEGF cells lead to behavioral improvement and prolonged survival in ALS model mice. These results suggest that the intrathecal transplantation of genetically modified human NSCs encoded with VEGF gene is a potentially useful treatment for ALS patients.
Materials and methods

Establishment of NSC line overexpressing human VEGF
The human NSC line, HB1.F3 (F3), 46, 53 was infected with a retrovirus encoding human VEGF165 gene and selected for puromycin resistance. A VEGF overexpressing clone, F3.VEGF, was isolated. Plasmid pLPCX.VEGF containing the full-length human VEGF cDNA was used in this study. PG13 mouse packaging cell line was transfected with pLPCX.VEGF vector (Figure 1a ) using LipofectA-MINE (Invitrogen, Carlsbad, CA, USA), and stable PG13 cell line were selected using 10 mg ml À1 puromycin for 3 days. Replication incompetent retroviral vector collected from PG13.VEGF cells was used for transfection of F3 human NSCs. Puromycin-resistant HB1.F3.VEGF (F3.VEGF) clones were isolated, screened and one of the clones F3.VEGF.D2 was expanded, and used for the transplantation. Expression of VEGF in F3.VEGF.D2 cell line was analyzed by reverse transcription-PCR, ELISA (R&D Systems, Minneapolis, MN, USA) and immunofluorescence microscopy.
Immunocytochemistry in F3.VEGF NSCs
Immunocytochemical demonstration of VEGF protein in F3.VEGF human NSCs was performed as described previously.
28 F3.VEGF human NSCs plated on poly-L- Following immunostaining, cells were mounted on glass slides using gelvatol and viewed under an Olympus laser-scanning confocal microscope (Tokyo, Japan).
Animals and cell transplantation
Transgenic mice that overexpress human SOD1 carrying a G93A mutation were divided into three groups (n ¼ 10 in each group, PBS, F3 and F3.VEGF). Two types of human NSCs, F3 and F3.VEGF, were used in this study. At 70 days of age, animals were anesthetized with 9:1 mixture of ketamine (10 mg ml
À1
) and rompun (10 mg ml À1 ), and received intrathecal injection of 5 ml PBS containing F3 or F3.VEGF cells (1 Â 10 5 cells) through the bilateral intervertebral space of the L5 or L6 spinous process. A modified version of an intrathecal injection method was used. 54 
Behavioral testing
Motor strength and motor coordination were evaluated with a Rotarod (Columbus Instruments, Columbus, OH, USA) after 1-week learning period, beginning at 10 weeks of age. The amount of time mice remained on the rotarod that was rotating at a constant speed of 16 r.p.m. was measured and 300 s was chosen as the arbitrary cutoff time. The animals performed the test twice a week until they could no longer perform the task. Paw grip endurance was used as the index of grip strength of the animal. The wire-lid was gently shaken to prompt the mouse to hold onto the grid before the lid was swiftly turned upside down. The latency of the mouse to let go off the grid with at least both hindlimbs was measured. Each mouse was allowed up to three attempts to hold onto the inverted lid for an arbitrary maximum of 200 s and the longest latency was recorded. An extension reflex was evaluated by the following 4-point scoring system: 4 for normal extension reflex of both hindlimbs, 3 for imbalance of extension in their hindlimbs, 2 for the extension reflex of only one hindlimb, 1 for the absence of any hindlimb extension and 0 for the total paralysis. Three tests per week were performed for paw grip endurance and the extension reflex. The time of death was defined as the date on which the mouse could no longer roll over within 30 s after being placed on its side.
Immunohistochemistry in spinal cord sections
To determine whether the transplanted cells survive and migrate into the spinal cord following intrathecal injection, the mice at 4 weeks post-transplantation were deeply anesthetized with chloral hydrate and perfused transcardially with 4% paraformaldehyde in 0. 
Western blot
SOD1G93A mice receiving intrathecal injection of PBS (control) or F3.VEGF human NSCs at 4 weeks posttransplantation were killed, spinal cord removed, and lumbar cords containing PBS/cell transplantation sites were dissected out and homogenized in 10 volumes of cold homogenization buffer (50 mM Tris, 120 mM NaCl, pH 7.4) containing protease inhibitors and stored at À80 1C. Protein extracts from brain tissue (50-100 mg) were separated by SDS-polyacrylamide gel electrophoresis. Protein separation was performed using a 10% polyacrylamide with 0.05% bis-acrylamide according to the published procedures. Proteins were then transferred to nitrocellulose, and the blots were probed with anticaspase 3 (1:1000, Santa Cruz Biotech, Santa Cruz, CA, USA), anti-Bax (1:1000, Santa Cruz), anti-Bcl-2 (1:1000, Santa Cruz) and anti-Bcl-XL (1:1000, Santa Cruz). Secondary antibodies (Amersham Life Science, Chicago, IL, USA) and a chemiluminescence kit (Amersham) were used for immunodetection.
Quantitative cell counts
Total number of human mitochondria antigen (HuMit)-positive F3 and F3.VEGF cells in the spinal cord sections was determined by stereological estimation. Actual counting was performed in whole spinal cord and the counting areas were divided into the surface and the parenchyma of spinal cord. Total of 40 sections were used for counting in one series. The serial sections with Human neural stem cells in mouse ALS model DH Hwang et al an equal distance (1 mm) from cervical to lumbar levels of spinal cord were counted under Olympus confocal laser scanning microscope (Model FV 300). The estimate of the total number of HuMit-positive F3 and F3.VEGF was calculated using the optical fractionator's formula. 55 
Statistical analysis
One-way analysis of variance was used to compare statistical differences among experimental groups in the onset time of abnormal behavior and the effect of VEGF on survival. Kaplan-Meier curves were used to assess survival analysis (SPSS 12.0, Chicago, IL, USA). A P-value o0.05 was used as the criterion for a significant statistical difference.
